Trump Administration Prepares 100-200% Tariffs on Drugmakers Without Price Deals
PFE sits 37% above its 52-week low of $20.915.
Summary
The Trump administration is reportedly preparing to announce new tariffs, potentially ranging from 100% to 200%, on drugmakers that have not secured deals guaranteeing low prices in the U.S. This policy aims to compel pharmaceutical companies to return manufacturing to the U.S. and reduce drug prices. While this represents a significant regulatory and political risk for the pharmaceutical sector, major companies including Pfizer (PFE) and Eli Lilly (LLY) have reportedly already struck deals with the White House, granting them a three-year reprieve from these specific levies. Therefore, the immediate direct impact on Pfizer is mitigated. Traders should monitor the official announcement for specific details, targeted companies, and any potential exemptions, as this policy signals ongoing government pressure on drug pricing and manufacturing for the broader industry.
At the time of this announcement, PFE was trading at $28.55 on NYSE in the Life Sciences sector, with a market capitalization of approximately $162.3B. The 52-week trading range was $20.92 to $28.64. This news item was assessed with neutral market sentiment and an importance score of 7 out of 10. Source: CNBC TV18.